阴性乳腺癌-话题@MedSci

#阴性乳腺癌#

226篇内容 | 3207人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2048052, encodeId=104f204805245, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, objectType=article, longId=196192, objectId=ea03196192c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea03196192c4, replyNumber=0, likeNumber=61, createdTime=2020-10-05, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea03196192c4, moduleTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea03196192c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048046, encodeId=30d520480466b, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出, objectType=article, longId=194255, objectId=475f19425533, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=475f19425533, replyNumber=0, likeNumber=72, createdTime=2020-11-12, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=475f19425533, moduleTitle=ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=475f19425533)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048055, encodeId=5ec620480555c, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, objectType=article, longId=197187, objectId=f91619e187c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f91619e187c8, replyNumber=0, likeNumber=62, createdTime=2020-10-06, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f91619e187c8, moduleTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f91619e187c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048041, encodeId=cd452048041e7, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=FDA批准靶向Trop-2的ADC药物Trodelvy，治疗三阴性乳腺癌, objectType=article, longId=192955, objectId=c84119295539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84119295539, replyNumber=0, likeNumber=69, createdTime=2021-03-20, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84119295539, moduleTitle=FDA批准靶向Trop-2的ADC药物Trodelvy，治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84119295539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048053, encodeId=fd992048053d5, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Nat Commun：厦门大学邓初夏团队：NOTCH1激活促进三阴性乳腺癌形成, objectType=article, longId=196680, objectId=48c7196680b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48c7196680b0, replyNumber=0, likeNumber=69, createdTime=2020-12-27, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48c7196680b0, moduleTitle=Nat Commun：厦门大学邓初夏团队：NOTCH1激活促进三阴性乳腺癌形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48c7196680b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048061, encodeId=59a020480616f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Res：全球首发！复旦大学发布三阴性乳腺癌精准治疗方案，让患者从山穷水尽到柳暗花明, objectType=article, longId=198384, objectId=332719838487, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=332719838487, replyNumber=0, likeNumber=59, createdTime=2020-12-10, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=332719838487, moduleTitle=Cell Res：全球首发！复旦大学发布三阴性乳腺癌精准治疗方案，让患者从山穷水尽到柳暗花明, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=332719838487)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048033, encodeId=fd712048033e3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JAMA Surg：三阴性乳腺癌、新辅助全身治疗与保乳治疗, objectType=article, longId=186268, objectId=fcc118626800, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcc118626800, replyNumber=0, likeNumber=59, createdTime=2020-07-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcc118626800, moduleTitle=JAMA Surg：三阴性乳腺癌、新辅助全身治疗与保乳治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcc118626800)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048045, encodeId=84ea2048045ca, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=“中国方案”实现全球三阴性乳腺癌辅助治疗新突破, objectType=article, longId=194092, objectId=c03c19409280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c03c19409280, replyNumber=0, likeNumber=34, createdTime=2020-11-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c03c19409280, moduleTitle=“中国方案”实现全球三阴性乳腺癌辅助治疗新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c03c19409280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048043, encodeId=949b204804339, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, objectType=article, longId=193172, objectId=24cd1931e229, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24cd1931e229, replyNumber=0, likeNumber=73, createdTime=2020-10-08, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24cd1931e229, moduleTitle=AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24cd1931e229)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048056, encodeId=c13c204805695, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JAMA Oncol：ctDNA和循环肿瘤细胞预测三阴性乳腺癌的复发风险, objectType=article, longId=197587, objectId=583719e5871f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=583719e5871f, replyNumber=0, likeNumber=62, createdTime=2020-07-19, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=583719e5871f, moduleTitle=JAMA Oncol：ctDNA和循环肿瘤细胞预测三阴性乳腺癌的复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=583719e5871f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048063, encodeId=879d20480630f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, objectType=article, longId=198983, objectId=4d33198983b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d33198983b2, replyNumber=0, likeNumber=63, createdTime=2021-03-19, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d33198983b2, moduleTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d33198983b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048031, encodeId=b070204803191, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Lancet：乳腺导管原位癌或淋巴结阴性乳腺癌术后放疗方案的选择, objectType=article, longId=184528, objectId=499218452828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=499218452828, replyNumber=0, likeNumber=59, createdTime=2020-01-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=499218452828, moduleTitle=Lancet：乳腺导管原位癌或淋巴结阴性乳腺癌术后放疗方案的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=499218452828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048050, encodeId=2e5b204805056, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ASCO：三阴性乳腺癌（TNBC）部分靶向药研究进展汇总, objectType=article, longId=195134, objectId=a16e195134a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a16e195134a3, replyNumber=0, likeNumber=145, createdTime=2021-01-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a16e195134a3, moduleTitle=ASCO：三阴性乳腺癌（TNBC）部分靶向药研究进展汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a16e195134a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048039, encodeId=8a282048039a6, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JCO：三阴性乳腺癌治疗“中国方案”全球首发，患者5年无病生存率提升6%（CBCSG010研究）, objectType=article, longId=192030, objectId=e87b192030fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e87b192030fa, replyNumber=0, likeNumber=69, createdTime=2020-10-30, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e87b192030fa, moduleTitle=JCO：三阴性乳腺癌治疗“中国方案”全球首发，患者5年无病生存率提升6%（CBCSG010研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e87b192030fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048035, encodeId=bf202048035db, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, objectType=article, longId=188050, objectId=0cde18805010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cde18805010, replyNumber=0, likeNumber=75, createdTime=2020-09-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cde18805010, moduleTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cde18805010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048032, encodeId=6c9d204803201, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, objectType=article, longId=185333, objectId=36af18533328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36af18533328, replyNumber=0, likeNumber=56, createdTime=2020-07-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36af18533328, moduleTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36af18533328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048065, encodeId=f17220480658d, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JAMA Oncol：三阴性乳腺癌治疗再添“白金方案”，五年无病生存率达86.5%, objectType=article, longId=199937, objectId=34c119993eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34c119993eb9, replyNumber=0, likeNumber=64, createdTime=2021-04-18, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34c119993eb9, moduleTitle=JAMA Oncol：三阴性乳腺癌治疗再添“白金方案”，五年无病生存率达86.5%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34c119993eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048057, encodeId=fd65204805ec8, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JAMA Oncology：三阴性乳腺癌新辅助化疗后ctDNA与CTCs阳性患者预后更差, objectType=article, longId=197657, objectId=bb3219e65783, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb3219e65783, replyNumber=0, likeNumber=56, createdTime=2021-05-14, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb3219e65783, moduleTitle=JAMA Oncology：三阴性乳腺癌新辅助化疗后ctDNA与CTCs阳性患者预后更差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb3219e65783)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048064, encodeId=78e32048064f8, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Eur J Surg Oncol：磁共振成像的早期评估可预测三阴性乳腺癌对新辅助化疗的病理反应, objectType=article, longId=198986, objectId=1b7719898601, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b7719898601, replyNumber=0, likeNumber=58, createdTime=2021-03-06, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b7719898601, moduleTitle=Eur J Surg Oncol：磁共振成像的早期评估可预测三阴性乳腺癌对新辅助化疗的病理反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b7719898601)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048029, encodeId=233f204802983, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=三阴性乳腺癌:畅言三阴进展，共话患者未来, objectType=article, longId=184051, objectId=6cdf18405112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cdf18405112, replyNumber=0, likeNumber=70, createdTime=2020-10-08, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cdf18405112, moduleTitle=三阴性乳腺癌:畅言三阴进展，共话患者未来, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cdf18405112)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阴性乳腺癌

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功

2020-10-05

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出

2020-11-12

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点

2020-10-06

heli0118 (审核中...)

前往app查看评论内容

#阴性乳腺癌#

FDA批准靶向Trop-2的ADC药物Trodelvy，治疗三阴性乳腺癌

2021-03-20

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Nat Commun：厦门大学邓初夏团队：NOTCH1激活促进三阴性乳腺癌形成

2020-12-27

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Res：全球首发！复旦大学发布三阴性乳腺癌精准治疗方案，让患者从山穷水尽到柳暗花明

2020-12-10

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JAMA Surg：三阴性乳腺癌、新辅助全身治疗与保乳治疗

2020-07-04

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

“中国方案”实现全球三阴性乳腺癌辅助治疗新突破

2020-11-04

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高

2020-10-08

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JAMA Oncol：ctDNA和循环肿瘤细胞预测三阴性乳腺癌的复发风险

2020-07-19

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到

2021-03-19

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Lancet：乳腺导管原位癌或淋巴结阴性乳腺癌术后放疗方案的选择

2020-01-24

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ASCO：三阴性乳腺癌（TNBC）部分靶向药研究进展汇总

2021-01-11

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JCO：三阴性乳腺癌治疗“中国方案”全球首发，患者5年无病生存率提升6%（CBCSG010研究）

2020-10-30

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功

2020-09-24

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA

2020-07-11

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JAMA Oncol：三阴性乳腺癌治疗再添“白金方案”，五年无病生存率达86.5%

2021-04-18

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JAMA Oncology：三阴性乳腺癌新辅助化疗后ctDNA与CTCs阳性患者预后更差

2021-05-14

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Eur J Surg Oncol：磁共振成像的早期评估可预测三阴性乳腺癌对新辅助化疗的病理反应

2021-03-06

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

三阴性乳腺癌:畅言三阴进展，共话患者未来

2020-10-08

科室
- - 订阅+
  - 更多科室
工具
服务